Adalimumab Injection, Solution
Product Images NDC 61314-332

Product Visual Gallery

This gallery contains 42 technical images submitted to the FDA as part of the official labeling for Adalimumab (NDC 61314-332). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Adalimumab 01)

A line chart comparing the percentage of ACR 20 responders over time (weeks) between two groups: one receiving 40 mg of Adalimumab every other week and a placebo group. The chart shows a higher and sustained response in the Adalimumab group across the 48-week period.*

FDA Label Image

Figure-2 (Adalimumab 02)

A line graph comparing the percentage of ASAS 20 response over 26 weeks between Adalimumab and placebo groups. The x-axis represents time in weeks, and the y-axis represents the percentage response. The Adalimumab group (N=208) shows a higher response rate than the placebo group (N=107) throughout the period.*

FDA Label Image

Figure-3a (Adalimumab 03)

A line graph showing treatment failure rates over time (up to 19 months) comparing placebo and Adalimumab for a drug labeled Adalimumab injection solution. The x-axis represents time in months, and the y-axis shows the treatment failure rate as a percentage. Two distinct curves illustrate the differences in failure rates between the placebo group and the Adalimumab treatment group.*

FDA Label Image

Figure-3b (Adalimumab 04)

A line graph comparing treatment failure rates over 20 months for placebo and Adalimumab. The x-axis represents time in months, and the y-axis shows the treatment failure rate as a percentage. Two curves illustrate lower failure rates for Adalimumab compared to placebo across the study period.*

FDA Label Image

Figure-4 (Adalimumab 42)

A line graph comparing the probability of failing treatment over time (weeks) between Adalimumab and placebo groups. The x-axis represents time in weeks, and the y-axis represents the probability of failing treatment. Two lines display the trends: a solid line for Adalimumab and a dashed line for placebo, with sample sizes noted below the time scale.*

FDA Label Image

Figa (Adalimumab 05)

An instructional diagram of an injection syringe labeled with parts including needle cap, needle guard, viewing window showing label and expiration date, finger flange, needle guard wings, plunger, and plunger head. The illustration clarifies the components of the syringe used for subcutaneous injection.*

FDA Label Image

Figb (Adalimumab 06)

An instructional illustration showing four items arranged in sequence: a wipe labeled 'WIPE', a cotton ball, a container labeled 'SHARPS' for disposal, and a medical adhesive bandage. This image appears to depict steps or materials used for preparing and cleaning an injection site, disposing of sharps, and covering the site after injection.*

FDA Label Image

Figc (Adalimumab 07)

An illustration of a prefilled syringe designed for subcutaneous injection, showing the needle, barrel, plunger, and finger grips. The syringe is intended for administration of Adalimumab injection solution.*

FDA Label Image

Figd (Adalimumab 08)

An illustration of a prefilled injection syringe for Adalimumab injection, solution. The image shows the syringe with a needle cover, plunger, and finger grip, representing the subcutaneous injection dosage form for Adalimumab. No specific strength is noted in the image.*

FDA Label Image

Fige (Adalimumab 09)

An anatomical diagram of a male torso and upper legs highlighting shaded areas on the abdomen and front thighs. These areas appear to indicate recommended injection sites for subcutaneous administration.*

FDA Label Image

Figf (Adalimumab 10)

An instructional illustration showing a hand pinching the skin of a thigh with arrows indicating a circular motion. The image appears to demonstrate how to prepare the injection site for a subcutaneous injection of Adalimumab solution.*

FDA Label Image

Figg (Adalimumab 11)

An instructional illustration showing hands removing the protective cap from the needle of a subcutaneous injection device, likely for Adalimumab injection solution by Sandoz Inc. The image demonstrates how to properly detach the needle cover before administration.*

FDA Label Image

Figh (Adalimumab 12)

An instructional illustration showing a person administering a subcutaneous injection using a syringe. One hand holds the syringe at an angle to the skin, while the other hand stabilizes the injection site, demonstrating proper technique for injecting a solution under the skin.*

FDA Label Image

Figi (Adalimumab 13)

An instructional diagram showing the use of a prefilled syringe for subcutaneous injection. It illustrates a hand holding and pressing the syringe to inject into the skin, with two close-up insets highlighting finger placement and syringe mechanism. This relates to administration of Adalimumab injection solution.*

FDA Label Image

Figj (Adalimumab 14)

An instructional illustration showing a hand holding a prefilled syringe, positioned for subcutaneous injection. The thumb is pressing on the syringe's plunger to deliver the injection beneath the skin, indicated by arrows. This depicts the administration technique for the Adalimumab injection, solution.*

FDA Label Image

Figk (Adalimumab 15)

An illustration showing a hand holding a syringe with a protective cap being pulled off from the needle end, indicated by an upward arrow. This diagram likely depicts a step in preparing an injection for administration.*

FDA Label Image

Figl (Adalimumab 16)

Illustration showing a hand disposing of a used prefilled syringe into a sharps disposal container labeled 'SHARPS'. This is an instructional graphic related to safe disposal of injection devices for Adalimumab injection, solution.*

FDA Label Image

Figaa (Adalimumab 17)

An instructional diagram showing the labeled components of an injection pen device for Adalimumab injection solution. The parts identified include the needle, needle guard, cap, internal needle cover, and viewing window.*

FDA Label Image

Figbb (Adalimumab 18)

An instructional illustration showing four items in sequence: a wipe labeled 'WIPE', a cotton ball or pad, a sharps disposal container labeled 'SHARPS', and an adhesive bandage. This depicts supplies commonly used for preparing and caring for a subcutaneous injection site.*

FDA Label Image

Figcc (Adalimumab 19)

An illustration of an Adalimumab prefilled injection pen, showing a labeled "Viewing window" and the location of the expiration date (EXP) on the pen body. The pen is designed for subcutaneous injection of Adalimumab solution.*

FDA Label Image

Figdd (Adalimumab 20)

An anatomical illustration showing preferred subcutaneous injection sites for Adalimumab injection, solution. The image highlights the lower abdomen around the navel and the front of the thighs as appropriate areas for injection.*

FDA Label Image

Figee (Adalimumab 21)

An instructional illustration showing a hand pinching the skin on a thigh, pulling it up to prepare for a subcutaneous injection, with arrows indicating a small side-to-side motion of the needle under the skin.*

FDA Label Image

Figff (Adalimumab 22)

An instructional illustration showing hands removing the cap from a prefilled injection syringe. The syringe is designed for subcutaneous administration, consistent with Adalimumab injection solution usage guidance.*

FDA Label Image

Figgg (Adalimumab 23)

Illustration comparing the correct and incorrect orientations for holding an Adalimumab injection pen. The correct method shows the pen held vertically upright with a green check mark, while the incorrect method depicts the pen tilted at an angle with a black X mark.*

FDA Label Image

Figgg1 (Adalimumab 24)

Black and white instructional illustration showing a hand holding a syringe-like device vertically by the barrel, with the needle end pointing down. The image appears to demonstrate proper grip or preparation for subcutaneous injection for Adalimumab injection, solution.*

FDA Label Image

Fighh (Adalimumab 25)

An instructional illustration showing a hand holding a pre-filled Adalimumab injection pen or syringe in a vertical position with a downward arrow indicating the direction to press the device for subcutaneous injection.*

FDA Label Image

Figii (Adalimumab 26)

An instructional illustration showing a hand holding a syringe injection device with a green plunger inside, positioned above a surface. The image highlights the plunger area with a green dashed circle, likely demonstrating a step in preparing or administering a subcutaneous injection.*

FDA Label Image

Figjj (Adalimumab 27)

An illustration showing a hand holding a prefilled injection pen device, demonstrating the proper grip and orientation for subcutaneous injection of Adalimumab (adalimumab-adaz) injection solution.*

FDA Label Image

Figure-k (Adalimumab 28)

An instructional illustration showing a syringe positioned above a labeled sharps disposal container, with a downward arrow indicating the syringe should be disposed of into the sharps container.*

FDA Label Image

Figure 10a (Adalimumab 29)

An illustration of a subcutaneous injection device labeled with parts including the plunger rod, finger grip, and needle cap. The device appears designed for solution injection, consistent with adalimumab injection use.*

FDA Label Image

Figure 10b (Adalimumab 30)

An instructional illustration showing four items arranged sequentially: a wipe packet labeled 'WIPE,' a cotton ball or pad, a sharps disposal container labeled 'SHARPS,' and an adhesive bandage. This likely represents steps or materials for injection site preparation and post-injection care.*

FDA Label Image

Figure 10c (Adalimumab 31)

Illustration showing appropriate subcutaneous injection sites for Adalimumab injection, solution. Dark shaded areas indicate the lower abdomen and the front of both thighs as recommended injection locations for subcutaneous delivery.*

FDA Label Image

Figure 10d (Adalimumab 32)

An instructional illustration showing a hand pressing and moving an injection device in a circular motion against the thigh area, demonstrating the technique for administering a subcutaneous injection of Adalimumab solution.*

FDA Label Image

Figure 10e (Adalimumab 33)

An instructional diagram showing the removal of a needle cap from a syringe held by one hand, with the other hand pulling the cap away. The syringe is designed for subcutaneous injection, consistent with a typical injection preparation step for Adalimumab injectable solution.*

FDA Label Image

Figure 10f (Adalimumab 34)

An instructional illustration showing a hand holding a syringe at a 45-degree angle to the skin of a finger, demonstrating the correct technique for subcutaneous injection. The syringe is positioned just above the injection site with a liquid drop visible at the needle tip.*

FDA Label Image

Figure 10g (Adalimumab 35)

An instructional illustration showing how to use a syringe for subcutaneous injection. It depicts a person holding a syringe and pressing the plunger with a thumb, injecting into the skin of a finger. A magnified inset highlights the plunger mechanism being pushed during the injection process.*

FDA Label Image

Figure 10h (Adalimumab 36)

Illustration showing a hand holding a syringe with a drop at the tip, positioned over a sharps disposal container labeled 'SHARPS,' indicating proper disposal of used needles or syringes.*

FDA Label Image

40-04 Pen (Adalimumab 37)

Adalimumab-adaz injection label for a subcutaneous solution with strength 40 mg/0.4 mL. The carton contains 2 single-dose prefilled Sensoready pens. The product is labeled for prescription use by Sandoz Inc and includes instructions about the enclosed Medication Guide and prescribing information. The label also notes that the prefilled syringe and injection device are latex-free.*

FDA Label Image

40-04pfs (Adalimumab 38)

Adalimumab-adaz Injection 40 mg/0.4 mL label for subcutaneous use by Sandoz Inc. The packaging indicates it contains 2 single-dose prefilled syringes with needle guards. The label notes it is sterile, preservative-free, and the syringes are latex-free. Additional contents include prescribing information, a medication guide, and a quick reference guide.*

FDA Label Image

20-02pfs (Adalimumab 39)

Adalimumab-adaz Injection 20 mg/0.2 mL prefills in single-dose prefilled syringes, for subcutaneous use. The carton contains 2 packs, each with 1 prefilled syringe, prescribing information, medication guide, and quick reference guide. Labeler is Sandoz Inc. The packaging highlights that the syringe is latex-free and that the product is sold under the brand name Hyrimoz.*

FDA Label Image

80-08-pen (Adalimumab 40)

Label for Adalimumab-adaz injection, 80 mg/0.8 mL, a subcutaneous solution by Sandoz Inc. The carton contains 2 single-dose prefilled Sensoready pens, needle gauge and length specified, with prescribing info and medication guide. Medication is sterile and latex-free, indicated for subcutaneous use only.*

FDA Label Image

10-01pfs (Adalimumab 41)

Adalimumab-adaz 10 mg/0.1 mL injection, solution for subcutaneous use, packaged as 2 single-dose prefilled syringes. The label includes the NDC 61314-391-64, prescribing information, and a syringe illustration. Manufactured by Sandoz, the sterile solution contains no preservatives and is latex-free.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.